Stapled peptide-based membrane fusion inhibitors of hepatitis C virus

被引：60
|
作者：
Cui, Hong-Kui [1 ]
Qing, Jie [1 ]
Guo, Ye [1 ]
Wang, Yu-Jia [1 ]
Cui, Li-Jia [2 ,3 ]
He, Tian-Hua [2 ,3 ]
Zhang, Linqi [2 ,3 ]
Liu, Lei [1 ]
机构：
[1] Tsinghua Univ, Dept Chem, Tsinghua Peking Ctr Life Sci,Minist Educ, Key Lab Bioorgan Phosphorus Chem & Chem Biol, Beijing 100084, Peoples R China
[2] Tsinghua Univ, Sch Med, Comprehens AIDS Res Ctr, Beijing 100084, Peoples R China
[3] Tsinghua Univ, Sch Med, Res Ctr Publ Hlth, Beijing 100084, Peoples R China
来源：
BIOORGANIC & MEDICINAL CHEMISTRY | 2013年 / 21卷 / 12期
基金：
中国国家自然科学基金;
关键词：
Hepatitis C virus; Stapled peptide; Protein-protein interaction; CELL-CULTURE SYSTEMS; B TYPE-I; OLEFIN METATHESIS; ALPHA-HELICES; BH3; HELIX; CD81; ENTRY; INFECTION; PROTEINS; RECEPTOR;
D O I：
10.1016/j.bmc.2013.02.011
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The strategy of peptide stapling was used to develop new molecules to inhibit the hepatitis C virus infection via disrupting the binding of HCV envelope glycoprotein E2 with human cell surface protein CD81. The peptide sequence was designed based on the large extra-cellular loop of CD81 with known importance in the HCV E2 binding interaction. Our results showed that the stapled peptides exhibited significantly higher alpha-helicity and proteolytic stability as compared to their linear peptide counterpart. The optimal compound was found to have an EC50 value of ca. 17-39 mu M against different HCV subtypes and represented a new HCV membrane fusion inhibitor. (C) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码：3547 / 3554
页数：8
相关论文
共 50 条
  • [41] Peptide-Based Inhibitors of Fimbrial Biogenesis in Porphyromonas gingivalis
    Alaei, Sarah R.
    Park, Jin Ho
    Walker, Stephen G.
    Thanassi, David G.
    INFECTION AND IMMUNITY, 2019, 87 (03)
  • [42] Peptide-based inhibitors of protein-protein interactions
    Wojcik, Paulina
    Berlicki, Lukasz
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (03) : 707 - 713
  • [43] C-terminal constrained phenylalanine as a pharmacophoric unit in peptide-based proteasome inhibitors
    Baldisserotto, Anna
    Marastoni, Mauro
    Lazzari, Ilaria
    Trapella, Claudio
    Gavioli, Riccardo
    Tomatis, Roberto
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2008, 43 (07) : 1403 - 1411
  • [44] Peptide-based inhibitors of amyloid beta aggregation and toxicity
    Rodriguez, Maria Zabala
    Teter, Ken
    Tatulian, Suren
    BIOPHYSICAL JOURNAL, 2023, 122 (03) : 352A - 353A
  • [45] Design and study of peptide-based inhibitors of amylin cytotoxicity
    Muthusamy, Karen
    Arvidsson, Per I.
    Govender, Patrick
    Kruger, Hendrik G.
    Maguire, Glenn E. M.
    Govender, Thavendran
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (04) : 1360 - 1362
  • [46] The development of peptide-based inhibitors of Stat3α
    Ren, Z
    Coleman, DR
    Cabell, LA
    McMurray, JS
    BIOPOLYMERS, 2003, 71 (03) : 392 - 392
  • [47] Peptide-Based Proteasome Inhibitors in Anticancer Drug Design
    Micale, Nicola
    Scarbaci, Kety
    Troiano, Valeria
    Ettari, Roberta
    Grasso, Silvana
    Zappala, Maria
    MEDICINAL RESEARCH REVIEWS, 2014, 34 (05) : 1001 - 1069
  • [48] Peptide-based Inhibitors of Amyloid Beta Oligomerization and Toxicity
    Rodriguez, Maria Zabala
    Tatulian, Suren
    Teter, Ken
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2024, 300 (03) : S769 - S769
  • [49] The development of peptide-based inhibitors of Stat3α
    Ren, Zhiyong
    Coleman, David R.
    Cabell, Larry A.
    McMurray, John S.
    PEPTIDE REVOLUTION: GENOMICS, PROTEOMICS & THERAPEUTICS, 2004, : 550 - 552
  • [50] Functional characterization of peptide-based anthrax toxin inhibitors
    Gujraty, Kunal
    Sadacharan, Skanda
    Frost, Mia
    Poon, Vincent
    Kane, Ravi S.
    Mogridge, Jeremy
    MOLECULAR PHARMACEUTICS, 2005, 2 (05) : 367 - 372
12345